Carl Langefeld to Tumor Suppressor Proteins
This is a "connection" page, showing publications Carl Langefeld has written about Tumor Suppressor Proteins.
Connection Strength
0.243
-
Freedman BI, Langefeld CD, Lu L, Divers J, Comeau ME, Kopp JB, Winkler CA, Nelson GW, Johnson RC, Palmer ND, Hicks PJ, Bostrom MA, Cooke JN, McDonough CW, Bowden DW. Differential effects of MYH9 and APOL1 risk variants on FRMD3 Association with Diabetic ESRD in African Americans. PLoS Genet. 2011 Jun; 7(6):e1002150.
Score: 0.097
-
Palmer ND, Mychaleckyj JC, Langefeld CD, Ziegler JT, Williams AH, Bryer-Ash M, Bowden DW. Evaluation of DLG2 as a positional candidate for disposition index in African-Americans from the IRAS Family Study. Diabetes Res Clin Pract. 2010 Jan; 87(1):69-76.
Score: 0.087
-
Xu J, Langefeld CD, Zheng SL, Gillanders EM, Chang BL, Isaacs SD, Williams AH, Wiley KE, Dimitrov L, Meyers DA, Walsh PC, Trent JM, Isaacs WB. Interaction effect of PTEN and CDKN1B chromosomal regions on prostate cancer linkage. Hum Genet. 2004 Aug; 115(3):255-62.
Score: 0.060